Irisin vs Insulin Degludec
Head-to-head comparison of Irisin (Irisin (FNDC5 cleavage product)) and Insulin Degludec (Insulin degludec (desB30, acylated ultra-long-acting insulin analog)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Irisin | Insulin Degludec |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Irisin (FNDC5 cleavage product) | Insulin degludec (desB30, acylated ultra-long-acting insulin analog) |
| Molecular Weight | ~12.3 kDa | 6103.9 Da |
| Half-Life | hours | More than 25 hours |
| Amino Acids | 112 | 50 |
| Typical Dose | No approved human dose; research use only | 0.1-0.2 U/kg once daily |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 79 | 7000 |
| Research Status | Pre-clinical | Approved |
Irisin Benefits
- ✓glucose homeostasis
- ✓energy expenditure
- ✓brown-fat activation
Insulin Degludec Benefits
- ✓Ultra-long basal coverage
- ✓Lower day-to-day variability
- ✓Reduced nocturnal hypoglycemia
- ✓Flexible dosing time
Irisin Dosing
not established|not established
Insulin Degludec Dosing
Inject SC once daily|Titrate to fasting glucose and HbA1c response|May be administered with flexible timing in adults
Irisin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Insulin Degludec Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Research Overview
Irisin
Irisin is widely explored in obesity and type 2 diabetes research because it connects exercise biology with metabolic adaptation. Human findings are mixed, so it remains a biomarker and preclinical lead rather than an approved therapy.
Insulin Degludec
Studies highlight prolonged action and lower glycemic variability compared with many other basal insulins. It is frequently used in research on ultra-long basal coverage and hypoglycemia reduction.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.